UPLOAD Filing
Aspire Biopharma Holdings, Inc.
Date: April 16, 2025 · CIK: 0001847345 · Accession: 0000000000-25-004018
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286444
Letter
Re: Aspire Biopharma Holdings, Inc. Registration Statement on Form S-1 Filed April 9, 2025 File No. 333-286444 Dear Kraig Higginson:
April 16, 2025
Kraig Higginson Chief Executive Officer Aspire Biopharma Holdings, Inc. 194 Candelaro Drive, #233 Humacao, PR 00791
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Arthur Marcus, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 16, 2025 Kraig Higginson Chief Executive Officer Aspire Biopharma Holdings, Inc. 194 Candelaro Drive, #233 Humacao, PR 00791 Re: Aspire Biopharma Holdings, Inc. Registration Statement on Form S-1 Filed April 9, 2025 File No. 333-286444 Dear Kraig Higginson: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Arthur Marcus, Esq. </TEXT> </DOCUMENT>